| Literature DB >> 31427479 |
Jens Spiesshoefer1, Simon Herkenrath2, Michael Mohr3, Winfired Randerath2, Izabela Tuleta4, Gerhard Paul Diller5, Michele Emdin6,7, Peter Young8, Carolin Henke9, Anca Rezeda Florian4, Ali Yilmaz4, Matthias Boentert9, Alberto Giannoni6,7.
Abstract
Background: Several determinants of exercise intolerance in patients with precapillary pulmonary hypertension (PH) due to pulmonary arterial hypertension and/or chronic thromboembolic PH (CTEPH) have been suggested, including diaphragm dysfunction. However, these have rarely been evaluated in a multimodal manner.Entities:
Keywords: diaphragm function; exercise tolerance; pulmonary hypertension; right heart failure
Mesh:
Substances:
Year: 2019 PMID: 31427479 PMCID: PMC6723707 DOI: 10.1042/BSR20190392
Source DB: PubMed Journal: Biosci Rep ISSN: 0144-8463 Impact factor: 3.840
Figure 1Standardised Diaphragm Ultrasound Protocol
Parameters measured during diaphragm ultrasound: diaphragm excursion during TB (A) and sniff maneuver (B); and diaphragm thickness at FRC (C) and TLC (D).
Demographic and clinical characteristics of the study population at baseline
| Patients with precapillary PH ( | Healthy volunteers ( | |
|---|---|---|
| Male, | 13 (30) | 13 (30) |
| Age, years | 57.8 ± 17.1 | 53.5 ± 12.6 |
| BMI, kg/m2 | 27.6 ± 6.7 | 28.9 ± 7.8 |
| BSA, m2 | 2.0 ± 0.2 | 2.0 ± 0.2 |
| NYHA class, | ||
| I | 1 (2) | - |
| II | 16 (37) | - |
| III | 25 (58) | - |
| IV | 1 (2) | - |
| Systolic PAP, mmHg | 51 ± 7 | - |
| RVEF, % | 50.1 ± 12.3 | - |
| Impaired RVEF, | 27 (63) | - |
| NT-proBNP, pg/ml | 860 (200–1159) | <50 |
| Capillary CO2, mmHg | 33.4 ± 4.3 | - |
| FVC, L | 2.62 ± 1.0 | 4.5 ± 1.1 |
| FVC, % predicted | 76.0 ± 18.2 | 106 ± 15 |
| FEV1/VC, % | 77 ± 10 | 81 ± 8 |
| PDE 5-I | 20 (49) | - |
| Dir.cGMP Stim | 5 (12) | - |
| ERA | 25 (61) | - |
| PCA | 6 (15) | - |
Values are mean ± standard deviation, median (interquartile range) or number of patients (%). Abbreviations: BSA, body surface area; Capillary CO2, capillary carbon dioxide level; Dir.cGMP Stim, direct cyclic guanosine monophosphate stimulator; ERA, endothelin receptor antagonist; FEV1, forced expiratory volume after 1 s; FVC, forced vital capacity; NT-proBNP, amino-terminal pro-brain natriuretic peptide; NYHA, New York Heart Association; PCA, prostacyclin analog; PDE 5-I, phosphodiesterase 5 inhibitor; RVEF, right ventricular ejection fraction.
P<0.05 vs patients with precapillary PH.
Diaphragm ultrasound measures in patients with precapillary PH and healthy volunteers
| Patients with precapillary PH ( | Healthy volunteers ( | ||
|---|---|---|---|
| Amplitude during TB, cm | 2.5 ± 1.8 | 1.6 ± 0.5 | |
| Velocity during TB, cm/s | 1.7 ± 0.9 | 1.1 ± 0.4 | |
| Amplitude during VS, cm | 2.9 ± 1.0 | 2.6 ± 1.1 | 0.116 |
| Velocity during VS, cm/s | 4.5 ± 1.7 | 6.8 ± 2.3 | |
| Amplitude during maximal inspiration, cm | 5.0 ± 1.3 | 7.8 ± 1.9 | |
| FRC, cm | 0.23 ± 0.09 | 0.20 ± 0.07 | 0.309 |
| TLC, cm | 0.37 ± 0.11 | 0.53 ± 0.19 | |
| Thickening ratio | 1.7 ± 0.5 | 2.8 ± 0.8 |
Values are mean ± standard deviation.
Characteristics of precapillary PH patients dichotomized by 6MWD
| Patients with precapillary PH | |||
|---|---|---|---|
| 6MWD <377 m ( | 6MWD ≥377 m ( | ||
| Age, years | 64.5 ± 14.5 | 51.5 ± 17.1 | |
| Male, | 4 (19) | 9 (41) | 0.127 |
| BMI, kg/m2 | 27.04 ± 5.6 | 28.2 ± 7.7 | 0.907. |
| BSA, m2 | 2.0 ± 0.2 | 2.0 ± 0.2 | 0.847 |
| NYHA class, | |||
| I | 0 | 1 (5) | 0.690. |
| II | 6 (29) | 10 (45) | 0.569 |
| III | 12 (57) | 13 (59) | 0.754 |
| IV | 1 (5) | 0 | 0.785 |
| Systolic PAP, mmHg | 47 ± 7 | 53 ± 7 | 0.124 |
| RVEF, % | 44.9 ± 12.6 | 55.1 ± 9.8 | |
| NT-proBNP, ng/l | 1000 (557–2689) | 450 (109–1000) | |
| FVC, % predicted | 72.6 ± 18.3 | 81.6 ± 14.9 | 0.217 |
| Capillary CO2, mmHg | 31 ± 4 | 35 ± 4 | |
| Amplitude during TB, cm | 2.4 ± 2.3 | 2.5 ± 1.2 | 0.243 |
| Velocity during TB, cm/s | 1.7 ± 0.7 | 1.7 ± 1.0 | 0.836 |
| Amplitude during VS, cm | 2.8 ± 0.8 | 3.0 ± 1.1 | 0.498 |
| Velocity during VS, cm/s | 3.4 ± 1.0 | 5.7 ± 1.5 | |
| Amplitude during maximal inspiration, cm | 4.8 ± 1.3 | 5.2 ± 1.3 | 0.308 |
| FRC, cm | 0.26 ± 0.08 | 0.20 ± 0.08 | |
| Thickening ratio | 1.5 ± 0.3 | 2.0 ± 0.5 | |
Values are mean ± standard deviation, median (interquartile range) or number of patients (%). Abbreviations: BSA, body surface area; Capillary CO2, capillary carbon dioxide level; NT-proBNP, N-terminal pro-brain natriuretic peptide; PCA, prostacyclin analog; PDE 5-I, phosphodiesterase 5 inhibitor. Significant P-values are represented in bold.
Figure 2Diaphragm velocity during a VS maneuver (top) and DTR (bottom) in controls (left blue box plot) versus patients with precapillary PH and less (6WMD ≥377 m) (mid box light red plot) or more (6MWD <377 m) (right dark red box plot) pronounced exercise intolerance (all P<0.01; see Tables 1 and 2)
Predictors of 6MWD
| Univariate analysis | Multivariate analysis | |
|---|---|---|
| Systolic PAP | - | - |
| RVEF | r = 0.58; | r = 0.47; |
| NT-pro-BNP | r = −0.46; | r = −0.27; |
| Respiratory variables | ||
| Capillary CO2 | r = 0.52; | - |
| FVC | - | - |
| Amplitude during TB | ||
| Velocity during TB | - | - |
| Amplitude during VS | - | - |
| Velocity during VS | r = 0.39; | - |
| Amplitude during maximal inspiration | - | - |
| Thickness at FRC | - | - |
| Thickening ratio | r = 0.36; | - |
Abbreviations: Capillary CO2, capillary carbon dioxide level; NT-pro-BNP, amino-terminal pro-brain natriuretic peptide.
Figure 3Correlation between RVEF and distance achieved in 6-min walking test (6MWD) in patients with precapillary PH